NCT06665828View on ClinicalTrials.gov

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

REGN9533

Administered per the protocol

DRUG

Matching Placebo

Administered per the protocol.

Trial Locations (1)

B-2650

RECRUITING

SGS Belgium NV_Edegem, Edegem

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06665828 - Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults | Biotech Hunter | Biotech Hunter